You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR AGRYLIN


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for AGRYLIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00648024 ↗ Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg Completed Mylan Pharmaceuticals Phase 1 2003-01-01 The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fasting conditions.
NCT00648765 ↗ Fed Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg Completed Mylan Pharmaceuticals Phase 1 2003-01-01 The objective of this study was to investigate the bioequivalence of Mylan's anagrelide HCl 1 mg capsules to Shire US's Agrylin® 1 mg capsules following a single, oral 1 mg (1 x 1 mg) dose administration under fed conditions.
NCT01467661 ↗ Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia Completed Shire Phase 3 2010-10-27 The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for AGRYLIN

Condition Name

Condition Name for AGRYLIN
Intervention Trials
Healthy 2
Essential Thrombocythemia (ET) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for AGRYLIN
Intervention Trials
Thrombocytosis 1
Thrombocythemia, Essential 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for AGRYLIN

Trials by Country

Trials by Country for AGRYLIN
Location Trials
Japan 18
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for AGRYLIN
Location Trials
North Dakota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for AGRYLIN

Clinical Trial Phase

Clinical Trial Phase for AGRYLIN
Clinical Trial Phase Trials
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for AGRYLIN
Clinical Trial Phase Trials
Completed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for AGRYLIN

Sponsor Name

Sponsor Name for AGRYLIN
Sponsor Trials
Mylan Pharmaceuticals 2
Shire 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for AGRYLIN
Sponsor Trials
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.